ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Folic Acid; Pemetrexed

Criteria

Inclusion Criteria:

• Histologic or cytologic diagnosis of metastatic or locally advanced cancer

• Prior chemotherapy is allowed

• Adequate bone marrow, liver and kidney function

Exclusion Criteria:

• Prior treatment with ALIMTA

• Brain metastasis

• Pregnancy or breast feeding